ID   NCI-H513
AC   CVCL_A570
SY   H513; H-513; NCIH513; HUT513
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-5830
DR   BioSample; SAMN03151854
DR   Cell_Model_Passport; SIDM00114
DR   Cosmic; 877271
DR   Cosmic; 877408
DR   Cosmic; 980997
DR   Cosmic; 1032388
DR   Cosmic; 1152503
DR   Cosmic; 1995420
DR   Cosmic-CLP; 1240141
DR   DepMap; ACH-002138
DR   DepMap; ACH-002341
DR   EGA; EGAS00001000978
DR   GDSC; 1240141
DR   GEO; GSM1669835
DR   KCLB; 90513
DR   PharmacoDB; H513_438_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54908072
RX   PubMed=8806092;
RX   PubMed=11030152;
RX   PubMed=16630136;
RX   PubMed=23830731;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31803961;
RX   PubMed=35839778;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v13_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a NCI-H125 derivative. Originally thought to originate with the pleural effusion of a mesothelioma in a 64 year old male patient.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00414.
CC   Population: African American.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=83.85%; Native American=0%; East Asian, North=2.18%; East Asian, South=0%; South Asian=2.16%; European, North=5.9%; European, South=5.9% (PubMed=30894373).
CC   Discontinued: ATCC; CRL-5830; true.
CC   Discontinued: DepMap; ACH-002341; true.
CC   Derived from site: Metastatic; Hypodermis; UBERON=UBERON_0002072.
ST   Source(s): ATCC=CRL-5830; Cosmic-CLP=1240141
ST   Amelogenin: X
ST   CSF1PO: 7
ST   D13S317: 11
ST   D16S539: 5,12
ST   D5S818: 10
ST   D7S820: 10
ST   TH01: 7
ST   TPOX: 8,9
ST   vWA: 17
DI   NCIt; C9133; Lung adenosquamous carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_3968 ! NCI-H125
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 02-05-24; Version: 30
//
RX   PubMed=8806092; DOI=10.1002/jcb.240630505;
RA   Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P.,
RA   McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr.,
RA   Carney D.N., Minna J.D., Mulshine J.L.;
RT   "NCI-Navy Medical Oncology Branch cell line data base.";
RL   J. Cell. Biochem. 63 Suppl. 24:32-91(1996).
//
RX   PubMed=11030152; DOI=10.1038/sj.onc.1203815;
RA   Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.;
RT   "Protein expression of the RB-related gene family and SV40 large T
RT   antigen in mesothelioma and lung cancer.";
RL   Oncogene 19:4632-4639(2000).
//
RX   PubMed=16630136; DOI=10.1111/j.1349-7006.2006.00184.x;
RA   Usami N., Fukui T., Kondo M., Taniguchi T., Yokoyama T., Mori S.,
RA   Yokoi K., Horio Y., Shimokata K., Sekido Y., Hida T.;
RT   "Establishment and characterization of four malignant pleural
RT   mesothelioma cell lines from Japanese patients.";
RL   Cancer Sci. 97:387-394(2006).
//
RX   PubMed=23830731; DOI=10.1016/j.cancergen.2013.04.006;
RA   Klorin G., Rozenblum E., Glebov O.K., Walker R.L., Park Y.,
RA   Meltzer P.S., Kirsch I.R., Kaye F.J., Roschke A.V.;
RT   "Integrated high-resolution array CGH and SKY analysis of homozygous
RT   deletions and other genomic alterations present in malignant
RT   mesothelioma cell lines.";
RL   Cancer Genet. 206:191-205(2013).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31803961; DOI=10.1002/jcb.29564;
RA   Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.A.,
RA   Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M.,
RA   Aldige C.R., Wistuba I.I., Minna J.D.;
RT   "From clinical specimens to human cancer preclinical models -- a journey
RT   the NCI-cell line database-25 years later.";
RL   J. Cell. Biochem. 121:3986-3999(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//